22112 MASE Chapter Meeting

In this educational initiative, an expert in the management of Cushing’s disease will describe best practices for diagnosis and treatment to improve long-term outcomes for patients.

Cushing’s disease is a serious endocrine disorder caused by a pituitary tumor that secretes excessive adrenocorticotropic hormone (ACTH), which stimulates the adrenal glands to overproduce cortisol. Cushing’s disease is usually characterized by a diagnostic delay, which contributes to development of multiple and severe comorbidities, impairment of quality of life, and increased mortality, compared with the healthy population. First-line treatment for most patients is transsphenoidal surgery; however, additional secondline treatments are often needed because persistent or recurrent Cushing’s disease after surgery has been found in approximately one-third of patients. For these patients or in situations where surgery or radiotherapy are not possible, medical therapies are used. Several options with various mechanisms of action are available;however, Cushing’s disease remains a difficult-to-treat disorder that often necessitates a multimodal treatment approach. New and emerging pharmacologic therapies are providing effective and well tolerated treatment options. In this educational initiative, an expert in the management of Cushing’s disease will describe best practices for diagnosis and treatment to improve long-term outcomes for patients.
 

Login to your Account